Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies

Journal of Infectious Diseases

Volumn 204, Issue 6, 2011, Pages 837-844

  Verstrepen, Babs E ^a   Depla, Erik ^b,f   Rollier, Christine S ^a,g   Mares, Gwenny ^b,f   Drexhage, Joost A R ^a   Priem, Sofie ^b,f   Verschoor, Ernst J ^a   Koopman, Gerrit ^a   Granier, Christelle ^c,d   Dreux, Marlène ^c,d   Cosset, Francxois L ^c,d   Maertens, Geert ^b   Heeney, Jonathan L ^a,e  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b INNOGENETICS   (Belgium)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f ABLYNX NV   (Belgium)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENOTYPE; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; IMMUNIZATION; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; PAN TROGLODYTES; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 80052186961     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir423     Document Type: Article

References (26)

1. Sabahi A. Hepatitis C Virus entry: The early steps in the viral replication cycle. Virol J 2009; 6:117.
2. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961-6.
3. Op De Beeck A, Cocquerel L, Dubuisson J. Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol 2001; 82:2589-295.
4. Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol 2006; 87:1075-84.
5. Perez-Berna AJ, Moreno MR, Guillen J, Bernabeu A, Villalain J. The membrane-active regions of the hepatitis C virus E1 and E2 envelope glycoproteins. Biochemistry 2006; 45:3755-68.
6. Keck ZY, Sung VM, Perkins S, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol 2004; 78:7257-63.
7. Meunier JC, Russell RS, Goossens V, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J Virol 2008; 82:966-73.
8. Rollier C, Depla E, Drexhage JA, et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol 2004; 78:187-96. (Pubitemid 37549731)
9. Leroux-Roels G, Depla E, Hulstaert F, et al. A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers. Vaccine 2004; 22:3080-6.
10. Sandrin V, Boson B, Salmon P, et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100:823-32. (Pubitemid 34832607)
11. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633-42. (Pubitemid 36314658)
12. Bartosch B, Verney G, Dreux M, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005; 79:8217-829.
13. Gerken G, Pontisso P, Roggendorf M, et al. Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol 1996; 24:33-7. (Pubitemid 26037203)
14. Rollier CS, Paranhos-Baccala G, Verschoor EJ, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007; 45:602-13. (Pubitemid 46450611)
15. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994; 91:1294-8.
16. Lavillette D, Tarr AW, Voisset C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005; 41:265-74. (Pubitemid 40173981)
17. Okamoto H, Kojima M, Okada S, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190:894-9.
18. Rehermann B. Cellular immune response to the hepatitis C virus. J Viral Hepat 1999; 6(Suppl 1):31-5. (Pubitemid 29349786)
19. Diepolder HM, Gruener NH, Heeney J. Of chimps and men-finding the path to an HCV vaccine. Hepatology 2003; 37:1472-4.
20. Youn JW, Park SH, Lavillette D, et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 2005; 42:1429-36.
21. Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139:965-74.
22. Petit MA, Jolivet-Reynaud C, Peronnet E, Michal Y, Trepo C. Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope. J Biol Chem 2003; 278:44385-92.
23. Owsianka AM, Tarr AW, Keck ZY, et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 2008; 89:653-9.
24. Rosa D, Campagnoli S, Moretto C, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996; 93:1759-63.
25. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005; 280:7793-9.
26. Barth H, Schnober EK, Neumann-Haefelin C, et al. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol 2008; 82:3466-79.